Abuse-deterrent formulations: Part 2: commercial products and proprietary technologies

Bibliography

• Manchikanti L, Atluri S, Candido KD, et al. Zohydro approval by Food and Drug Administration: controversial or frightening? Pain Physician 2014;17(4):E437-E50
   PubMed Web of Science ®Google Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14(4):351-8
   PubMed Web of Science ®Google Scholar
• Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain 2013;14(10):1122-30
   PubMed Web of Science ®Google Scholar
• Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS®) System. Abuse deterrent formulations – Updated RADARS® system data. RADARS System Third Quarter Newsletter 2013;8(3)
   Google Scholar
• U.S. Food and Drug Administration. FDA approves abuse-deterrent labeling for reformulated OxyContin. 2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm [Last accessed 31 March 2014]
   Google Scholar
• Food and Drug Administration. (Draft) Guidance for industry, abuse-deterrent opioids-evaluation and labeling. 2013. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf [Last accessed 24 March 2014]
   Google Scholar
• Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend 2013;130(1-3):13-23
   PubMed Web of Science ®Google Scholar
• Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc 2012;87(7):683-94
   PubMed Web of Science ®Google Scholar
• Alexander L, Mannion RO, Weingarten B, et al. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend 2014;138:1-6
   PubMed Web of Science ®Google Scholar
• Lourenco LM, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use? Expert Opin Drug Deliv 2013;10(2):229-40
   PubMed Web of Science ®Google Scholar
• Covidien. FDA approves Mallinckrodt’s EXALGO® (hydromorphone HCl) extended-release tablets 32 mg (CII) for opioid-tolerant patients with moderate-to-severe chronic pain. 2012. Available from: http://www.covidien.com/investor [Last accessed 30 March 2014]
   Google Scholar
• DuPont RL, Lande SD. Impact of drug formulation: the impact of abuse deterrent formulation on the incidence of abuse and diversion of OROS methylphenidate. Drug Alcohol Depend 2006;83(Suppl 1):S83-9
   Google Scholar
• Hee Han D. Polyethylene oxide tapentadol ER formulation proves crush-resistant. Monthly Prescribing Reference (MPR), PAINWeek 2012 Neuropathic Pain 2012. Available from: http://www.empr.com/polyethylene-oxide-tapentadol-er-formulation-proves-crush-resistant/article/257976/ [Last accessed 31 March 2014]
   Google Scholar
• Pergolizzi J, Galia E, Williams Y, et al. Tamper-resistant properties of tapentadol extended-release tablets [poster]. Presented at the 2013 American Academy of Pain Medicine (AAPM) Annual Meeting. 2013. Available from: http://www.painmed.org/2013posters/abstract-125/ [ [Last accessed 31 March 2014]
   Google Scholar
• Moorman-Li R, Motycka CA, Inge LD, et al. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T 2012;37(7):412-18
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. FDA statement: original opana ER relisting determination. 2013. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm351357.htm [Last accessed 30 March 2014]
   Google Scholar
• Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005;6(10):662-72
   PubMed Web of Science ®Google Scholar
• Jayawant SS, Balkrishnan R. The controversy surrounding OxyContin abuse: issues and solutions. Ther Clin Risk Manag 2005;1(2):77-82
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. FDA approves new formulation for OxyContin®. 2010. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm [Last accessed 31 March 2014]
   Google Scholar
• Purdue Pharma L.P. Purdue meeting background materials, NDA 22-272 reformulated OxyContin®, joint meeting of the anesthetic and life support drugs advisory committee and drug safety and risk management advisory committee. 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4356b1-02-Purdue.pdf [Last accessed 31 March 2014]
   Google Scholar
• Mallinckrodt Pharmaceuticals. Xartmis Xr [Product homepage]. 2014. Available from: http://www.xartemisxr.com/ [Last accessed 17 April 2014]
   Google Scholar
• Mallinckrodt Pharmaceuticals. Mallinckrodt opioid safe use initiatives : oxycodone and Mallinckrodt’s abuse-deterrent technology [Presentation]. 2014. Available from: http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTM1OTA4fENoaWxkSUQ9MjI0MDAzfFR5cGU9MQ==&t=1 [Last accessed 6 June 2014]
   Google Scholar
• Singla N. A randomized, double-blind, placebo-controlled, phase 3 study of the safety and analgesic efficacy of MNK-795 controlled-release oxycodone/acetaminophen tablets (CR OC/APAP) in an acute pain model [Oral Presentation]. Pain Week 2013. Available from: http://www.lotuscr.com/lotus-pdf/Mallinckrodt-MNK795-PainWeek2013-OralPresentation_101.pdf [Last accessed 17 April 2014]
   Google Scholar
• EMBEDA®[package insert]. Pfizer; New York City, NY: 2013
   Google Scholar
• Alpharma Pharmaceuticals LLC. EMBEDA®extended release capsules: joint anesthetic and life support drugs (ALSDAC) and drug safety and risk management (DSaRM) advisory committee briefing document. 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM230111.pdf [Last accessed 25 June 2014]
   Google Scholar
• Johnson FK, Ciric S, Boudriau S, et al. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol 2012;52(5):747-56
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Embeda®: important information for patients and prescribers. Available from: http://embeda.com/ [Last accessed 20 Feb 2014]
   Google Scholar
• Pfizer, Inc. Pfizer receives FDA approval for a prior approval supplement for EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended release capsules CII. 2013. Available from: http://www.pfizer.com/news/press-release/press-release-archive-detail/pfizer_receives_fda_approval_for_a_prior_approval_supplement_for_embeda_morphine_sulfate_and_naltrexone_hydrochloride_extended_release_capsules_cii [Last accessed 20 July 2014]
   Google Scholar
• Mehta AM. inventor. Abuse-resistant oral dosage forms and method of use thereof. US8182836; 2012
   Google Scholar
• Mehta AM. inventor. Abuse-resistant oral dosage forms and method of use thereof. US8425933; 2013
   Google Scholar
• Elite Pharmaceuticals, Inc. Recent Press Releases. 2014. Available from: http://www.elitepharma.com/ [Last accessed 29 March 2014]
   Google Scholar
• Reckitt Benckiser Pharmaceuticals, Inc. SUBOXONE film, key benefits. 2013. Available from: http://www.suboxone.com/hcp/about_suboxone/key_benefits.aspx [Last accessed 20 February 2014]
   Google Scholar
• Baum C, Hsu JP, Nelson RC. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep 1987;102(4):426-9
   PubMed Web of Science ®Google Scholar
• Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm 2013;39(5):611-24
   PubMed Web of Science ®Google Scholar
• Purdue Pharma L.P. FDA accepts for review Purdue Pharma’s new drug application for Targiniq™ ER (oxycodone HCl/naloxone HCL controlled-release) tablets CII. 2013. Available from: [http://www.purduepharma.com/news-media/2013/11/] [Last accessed 22 July 2014]
   Google Scholar
• Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23(4):419-27
   PubMed Web of Science ®Google Scholar
• Dew RE, Kollins SH. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opin Pharmacother 2010;11(17):2907-13
   PubMed Web of Science ®Google Scholar
• Mehra A, Sarkar S, Basu D. Lomotil (diphenoxylate) dependence in India. Indian J Psychol Med 2013;35(3):248-50
   PubMedGoogle Scholar
• Woods JH, Winger G. Abuse liability of flunitrazepam. J Clin Psychopharmacol 1997;17(3 Suppl 2):1S-57S
   PubMed Web of Science ®Google Scholar
• Martinez A, Rougeot O, Yaguchi Y. inventors. Pharmaceutical composition for oral administration intended to prevent misue. US0280326; 2013
   Google Scholar
• Tussigon®[package insert]. Monarch Pharmaceuticals, Inc; Bristol, TN: 2011
   Google Scholar
• Acura Pharmaceuticals, Inc. Acurox® with niacin tablets 2014. Available from: http://acurapharm.com/products/acurox-tablets/ [Last accessed 31 March 2014]
   Google Scholar
• Acura Pharmaceuticals, Inc. Study AP-ADF-107, a phase II single-center, randomized, double-blind study in fasted and non-fasted healthy volunteers to evaluate the dose response for flushing and safety and tolerability of escalating doses of niacin. 2011. Available from: http://acurapharm.com/products/acurox-tablets/study-ap-adf-107/ [Last accessed 19 February 2014]
   Google Scholar
• Acura Pharmaceuticals, Inc. Nexafed [Product Website]. 2012. Available from: http://www.nexafed.com/ [Last accessed 31 March 2014]
   Google Scholar
• Brzeczko AW, Leech R, Stark JG. The advent of a new pseudoephedrine product to combat methamphetamine abuse. Am J Drug Alcohol Abuse 2013;39(5):284-90
   PubMed Web of Science ®Google Scholar
• Westport Pharmaceuticals. Zephrex-D nasal decongestant unique formulation. 2012. Available from: http://zephrex-d.com/unique-formulation/ [Last accessed 31 March 2014]
   Google Scholar
• Marcenyac G, Alfonso M, Gehrlein L, et al. inventors. Disposal system for transdermal dosage form. US0262284; 2008
   Google Scholar
• Goldberg AP. inventor. Transdermal delivery form disposal systems and methods. US12048771; 2008
   Google Scholar
• Tavares L, Reidenberg BE, Sackler R, et al. inventors. Abuse resistant opioid containing transdermal systems. US0241218; 2004
   Google Scholar
• Cai B, Engqvist H, Bredenberg S. Evaluation of the resistance of a geopolymer-based drug delivery system to tampering. Int J Pharm 2014;465(1-2):169-74
   PubMed Web of Science ®Google Scholar
• Capsugel. ABUSOLVE Abuse Deterrent Formulations. 2014. Available from: http://capsugel.com/en/products-services/services/abusolve/ [Last accessed 3 March 2014]
   Google Scholar
• Ridgway D, Sopata M, Burneckis A, et al. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. J Pain Symptom Manage 2010;39(4):712-20
   PubMed Web of Science ®Google Scholar
• Andersen C, Lindhardt K, Oevergaard JM, inventors. Formulations and methods for the controlled release of active drug substances. US8563038; 2013
   Google Scholar
• Tygesen PH, Lindhardt K, Olsen MR, et al. inventors. Abuse deterrent pharmaceutical compositions for controlled release. US0010873; 2014
   Google Scholar
• Acura Pharmaceuticals, Inc. AVERSION® Technology. 2014. Available from: http://acurapharm.com/platforms/aversion-technology/ [Last accessed 26 March 2014]
   Google Scholar
• Kumar V, Dixon D, Tewari D, Wadgaonkar DB. inventors. Acura Pharmaceuticals, Inc., assignee. Methods and compositions for deterring abuse of opioid containing dosage forms. US7201920; 2007
   Google Scholar
• Kumar V, Dixon D, Tewari D, Wadgaonkar DB. inventors. Acura Pharmaceuticals, Inc., assignee. Methods and compositions for deterring abuse of opioid containing dosage forms. US7476402; 2009
   Google Scholar
• Kumar V, Dixon D, Tewari D, Wadgaonkar DB. inventors. Extended release opioid abuse deterrent compositions and methods of making same. US8101630; 2012
   Google Scholar
• Collegium Pharmaceutical. DETERx technology introduction. 2013. Available from: http://www.collegiumpharma.com/technology-introduction [Last accessed 4 December 2013]
   Google Scholar
• Hirsh J, Kibanov AM, Swager TM, et al. inventors. Abuse-deterrent pharmaceutical compositions of opiods and other drugs. US7399488; 2008
   Google Scholar
• Hirsh J, Fleming A, Rariy R, Klibanov AM. inventors. Abuse-deterrent drug formulations. US7771707; 2010
   Google Scholar
• Hirsh J, Fleming A, Rariy R, Kilbanov A. inventors. Abuse-deterrent drug formulations. US8449909; 2013
   Google Scholar
• Collegium Pharmaceutical. Collegium Pharmaceutical, Inc. Announces issuance of patent covering oxycodone DETERx®, an abuse-deterrent, extended-release opioid product. 2013. Available from: http://www.collegiumpharma.com/press-releases [Last accessed 25 March 2013]
   Google Scholar
• Bartholomaus J, Ashworth J, Stahlberg H-J, et al. Innovative formulation technology protecting intended drug action. Drug Dev Deliv 2012;12(8):69-75
   Google Scholar
• Bartholomaus J, Kugelmann H, Arkenau-Maric E. inventors; Abuse-proofed dosage form. US8114383; 2012
   Google Scholar
• Bartholomaus J, Schwier S, Brett M, et al. New abuse deterrent formulation (ADF) technology for immediate-release opioids. Drug Dev Deliv 2013;13(8):76-81
   Google Scholar
• Intellipharmaceutics International. Technology portfolio; products. 2014. Available from: http://www.intellipharmaceutics.com/ [Last accessed 27 March 2014]
   Google Scholar
• Odidi I, Odidi A. inventors. Pharmaceutical composition having reduced abuse potential. US0232887; 2009
   Google Scholar
• Ethypharm. Proprietary technologies: LOCKTAB®, protected by three patent families. Available from: http://www.ethypharm.com/drug-technologies/proprietary-technologies.html [Last accessed 2014 20 July]
   Google Scholar
• Trichard L. New trends in drug abuse deterrence: Locktab formulations to address drug misuse and abuse. 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Malta; 2010
   Google Scholar
• Cailly-Dufestel V, Herry C, Bacon J, Oury P. inventors. Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion. US8501160; 2013
   Google Scholar
• Tris Pharma, Inc. ABUSE RESISTANCE: nobuse™. 2014. Available from: http://www.trispharma.com/technologies_nobuse.php [Last accessed 27 March 2014]
   Google Scholar
• Mehta K, Tu Y-H, Chaudhuri A, Perumal A. inventors. Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings. WO119231; 2013
   Google Scholar
• Di-Filippo P. Abuse-deterrent formulations: developers try to head off an epidemic. Contract Pharma Magazine 2013
   Google Scholar
• DURECT Corp. ORADUR: oral Delivery Technology. 2012. Available from: http://www.durect.com/pdf/Durect_Oradur_Brochure_2012.pdf [Last accessed 26 March 2014]
   Google Scholar
• Yum SI, Schoenhard G, Tipton AJ, inventors. Oral drug delivery system. US8420120; 2013
   Google Scholar
• Yum SI, Schoenhard G, Tipton AJ, inventors. Oral drug delivery system. US8354124; 2013
   Google Scholar
• Yum SI, Schoenhard G, Tipton AJ, inventors. Oral drug delivery system. US8147870; 2012
   Google Scholar
• Yum SI, Schoenhard G, Tipton AJ, Gibson JW. inventors. Oral drug delivery system. US8153152; 2012
   Google Scholar
• Yum SI, Schoenhard G, Tipton AJ, Gibson JW. inventors. Oral drug delivery system. US8168217; 2012
   Google Scholar
• Yum SI, Schoenhard G, Tipton AJ, inventors. Oral drug delivery system. US8133507; 2012
   Google Scholar
• Pain Therapeutics, Inc. NDA 22-324 Remoxy XRT, advisory committee briefing materials for the anesthetic life support drugs advisory committee meeting of November 13, 2008. 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4395b1-02-PAIN.pdf [Last accessed 17 March 2011]
   Google Scholar
• Pain Therapeutics, Inc. FDA complete response letter received for REMOXY. 2011. Available from: http://investor.paintrials.com/releasedetail.cfm?ReleaseID=587311 [Last accessed 20 March 2011]
   Google Scholar
• DURECT Corp. ORADUR technology. 2014. Available from: http://www.durect.com/wt/durect/page_name/oradur [Last accessed 26 March 2014]
   Google Scholar
• Haswani D, Nagel JC, Moe D, Hamed E. OraGuard(TM): a tampering-deterrent & alcohol-resistant extended-release technology. Drug Dev Deliv 2012;12(8):42-50
   Google Scholar
• Habib W, Hamed E, Vega Zepeda MA. inventors. Abuse resistant drug formulation. US8445018; 2013
   Google Scholar
• Babul N. inventor. Multimodal abuse resistant and extended release opioid formulations. US0249045; 2010
   Google Scholar
• Babul N. inventor. Extended release oral pharmaceutical compositions of 3-hydroxy-N-methylmorphinan and method of use. US0065221; 2012
   Google Scholar
• Relmada Therapeutics. Development pipeline. 2013. Available from: www.relmada.com [Last accessed 2014 27 March 2014]
   Google Scholar
• Atlantic Pharmaceuticals, Inc. Abuse deterrebt oral delivery system (SMART/Script). 2013. Available from: http://www.atlanticpharma.com/technology.html [Last accessed 27 February 2014]
   Google Scholar
• Soscia AE, Peng Y, Sun Y, inventors. Dosage forms for tamper prone therapeutic agents. US8349362; 2013
   Google Scholar
• Soscia AE, Peng Y, Sun Y, inventors. Dosage forms for tamper prone therapeutic agents. US8187636; 2012
   Google Scholar
• Shukla AJ, Soscia AE, Peng Y, inventors. Dosage forms for tamper prone therapeutic agents. US8507001; 2013
   Google Scholar
• Vachon M, Rudnic EM. inventors. Technology for preventing abuse of solid dosage forms. US0321716; 2012
   Google Scholar
• Flamel Technologies SA. Trigger Lock drug delivery platform. 2014. Available from: http://www.flamel.com/wp-content/uploads/2013/12/Flamel-Technologies-Trigger-Lock-Drug-Delivery-Platform.pdf [Last accessed 26 March 2014]
   Google Scholar
• Guimberteau F, Dargelas F. inventors. Anti-misuse microparticulate oral pharmaceutical form. US8445023; 2013
   Google Scholar
• Shah MS, Difalco RJ. inventors. Abuse resistant drugs, method of use and method of making. US7955619; 2011
   Google Scholar
• Vinson RK. Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility. Clin Drug Investig 2012;32(7):487-95
   PubMed Web of Science ®Google Scholar
• Betancourt AO, Gosselin PM, Vinson RK. New immediate release formulation for deterring abuse of methadone. Pharm Dev Technol 2013;18(2):535-43
   PubMed Web of Science ®Google Scholar
• Vinson R, Gosseling P, Betancourt AO. inventors. Narcotic drug formulations with decreased abuse potential. US8460640; 2013
   Google Scholar
• Rahmouni M, Ferrada A, Soulhi F, et al. inventors. Misuse preventative, controlled release formulation. US0344142; 2013
   Google Scholar
• Rahmouni M, Ferrada A, Soulhi F, et al.inventors. Misuse preventative, controlled release formulation. US8486448; 2013
   Google Scholar
• Rahmouni M, Gervais S, Sant V, et al. inventors. Misuse preventative, controlled release formulation. US8486449; 2013
   Google Scholar
• Rahmouni M, Gervais S, Sant V, et al. inventors. Misuse preventative, controlled release formulation. US0004191; 2014
   Google Scholar
• Gervais S, Smith D, Contamin P, inventors. Sustained drug release composition. US0033537; 2011
   Google Scholar
• Purdue Pharma L.P. FDA grants priority review designation for Purdue Pharma’s once-daily hydrocodone bitartrate extended-release tablets formulated with abuse-deterrent properties. 2014. Available from: http://www.purduepharma.com/news-media/2014/07/ [Last accessed 22 July 2014]
   Google Scholar
• Brzeczko AW, Hollenbeck RG. inventors. Methods and compositions for self-regulated release of active pharmacetical ingredient. US0155388; 2014
   Google Scholar
• FDA center for drug evaluation and research, Division of anethesia, analgesia, and addition products. Nucynta ER: summary review for regulatory action NDA 200533. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200533Orig1s000SumR.pdf [Last accessed 6 March 2014]
   Google Scholar